Clinical Trials Logo
  1. Home
  2. Induction Chemotherapy
  3. NCT05397769

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Induction Chemotherapy Clinical Trial

Official title:
Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.

Clinical Trial Summary

Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05397769
Study type Interventional
Source Sun Yat-sen University
Contact Fei Han
Phone 13822113698
Email hanfei@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date June 8, 2022
Completion date December 31, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04539600 - Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer Phase 2
Completed NCT04473716 - Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Phase 1
Recruiting NCT06093438 - Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT04446130 - Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Phase 3
Recruiting NCT02924909 - Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer Phase 2
Active, not recruiting NCT04384627 - Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Phase 3
Recruiting NCT05114707 - Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses Phase 2
Recruiting NCT04083911 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 Phase 3
Recruiting NCT04087967 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients Phase 3